Publications by authors named "Si-Yi Lu"

Background: This study aimed to optimize a lateral transthyroid approach by using high-resolution ultrasonography (HRUS) for recurrent laryngeal nerve (RLN) visualization.

Patients And Methods: In this prospective study of 85 patients undergoing thyroidectomy, the RLN was visualized preoperatively by using a lateral transthyroid approach via HRUS. The inferior thyroid artery, thyroid nodule, and cricoid cartilage were used as landmarks.

View Article and Find Full Text PDF

Background: The features of gastric cancer based on the anatomic site remain unknown in northern China patients.

Aim: To analyze gastric cancer features and associated trends based on the anatomical site in northern China patients.

Methods: This cross-sectional study used incident gastric cancer case data from 10 Peking University-affiliated hospitals (2014 to 2018).

View Article and Find Full Text PDF

Tamoxifen is still the most commonly used endocrine therapy drug for estrogen receptor (ER)-positive breast cancer patients and has an excellent outcome, but tamoxifen resistance remains a great impediment to successful treatment. Recent studies have prompted an anti-tumor effect of aspirin. Here, we demonstrated that aspirin not only inhibits the growth of ER-positive breast cancer cell line MCF-7, especially when combined with tamoxifen, but also has a potential function to overcome tamoxifen resistance in MCF-7/TAM.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Si-Yi Lu"

  • - Si-Yi Lu's research encompasses significant studies on gastric cancer and breast cancer, highlighting specific anatomical features and treatment resistance.
  • - A notable multi-center study investigated the characteristics of gastric cancer based on its anatomical subsites among patients in northern China, utilizing extensive incident case data from multiple hospitals.
  • - In breast cancer research, Lu explored the role of aspirin in overcoming tamoxifen resistance, demonstrating its potential as an effective therapeutic agent in enhancing the efficacy of existing treatments for estrogen receptor-positive breast cancer.